lunedì, 4 maggio 2026

Notizie Newsletter

10 Settembre 2019

Trends in the Prevalence of Exposure to e-Cigarette Aerosol in Public Places Among US Middle and High School Students, 2015 to 2018

Approximately one-quarter of US youth were exposed to secondhand electronic cigarette (e-cigarette) aerosols between 2015 and 2017.1 Given the rapid increase in vaping and the popularity of pod-based e-cigarettes among youth,2 this survey study examines trends in and factors ...
Leggi tutto

9 Settembre 2019

ASCO Expands Therapeutic Options for Venous Thromboembolism Prophylaxis in Patients With Cancer

Sep 4, 2019 - ASCO has updated its recommendations for the prevention and treatment of venous thromboembolism (VTE) in patients with cancer. “The recommendations were last updated in 2015, but since then, new, significant publications have emerged, which prompted this ...
Leggi tutto

9 Settembre 2019

FDA Grants Nirogacestat Breakthrough Designation for Desmoid Tumors

Sep 4, 2019 - The FDA has granted a breakthrough therapy designation to the investigational gamma-secretase inhibitor nirogacestat (PF-03084014) for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis. ...
Leggi tutto

9 Settembre 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 September 2019

Sep 6, 2019 - EMA’s safety committee (PRAC) has started a review of data on skin cancer in patients using Ingenol mebutate (LEO), a gel for treating actinic keratosis, a skin condition caused by too much sunlight exposure. The review was triggered by data from several ...
Leggi tutto

9 Settembre 2019

Atezolizumab Combo Approved in Europe for Small Cell Lung Cancer

Sep 6, 2019 - The European Commission has approved atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of adult patients with extensive-stage small cell lung cancer, according to Roche (Genentech) the developer of the PD-L1 inhibitor. ...
Leggi tutto

9 Settembre 2019

Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Approved in Europe for Nonsquamous NSCLC

Sep 6, 2019 - The European Commission has approved atezolizumab for use in combination with carboplatin and nab-paclitaxel for the first-line treatment of adult patients with advanced, nonsquamous non–small cell lung cancer (NSCLC) who do not have EGFR or ALK molecular ...
Leggi tutto

9 Settembre 2019

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium

In metastatic renal-cell carcinoma (mRCC), recent data have shown efficacy of first-line ipilimumab and nivolumab (ipi-nivo) as well as immuno-oncology (IO)/vascular endothelial growth factor (VEGF) inhibitor combinations. Comparative data between these strategies are limited. ...
Leggi tutto

9 Settembre 2019

6 settembre 2019 – Comunicazione EMA su Ingenolo mebutato (LEO)

9 Settembre 2019

6 settembre 2019 – Aggiornamento sulla carenza del farmaco Bleomicina (Sanofi)

9 Settembre 2019

6 settembre 2019 – Chiusura Registro di monitoraggio Cabozantinib (Ipsen) (RCC)